Title : Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Pub. Date : 2018 May 14

PMID : 29657128






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Using whole-exome sequencing to examine non-small-cell lung cancer (NSCLC) treated with PD-1 plus CTLA-4 blockade, we found that high tumor mutation burden (TMB) predicted improved objective response, durable benefit, and progression-free survival. 1,2,4,5-tetramethoxybenzene cytotoxic T-lymphocyte associated protein 4 Homo sapiens
2 TMB should be incorporated in future trials examining PD-(L)1 with CTLA-4 blockade in NSCLC. 1,2,4,5-tetramethoxybenzene cytotoxic T-lymphocyte associated protein 4 Homo sapiens